Fig 4.
Blockade of the central 5HT2A receptors attenuates the anorexic and weight-loss effect of peripherally injected liraglutide. Daily peripheral (ip) injections of liraglutide (75 µg/kg) promoted weight loss; blockade of 5HT2A receptors concurrent with the liraglutide treatment abolished liraglutide-induced weight loss (A). In line with the body weight results, liraglutide reduced food intake, an effect that was attenuated by 5HT2A receptor antagonist treatment (B) n = 7–10 per each treatment group. Data are presented as mean ± SEM.*p < 0.05, **p < 0.01 compared to vehicle-treated rats.